on KLEA HOLDING (isin : FR0013481835)
Klea Pharmaceuticals begins its growth in the Middle East
Klea Pharmaceuticals, a subsidiary of KLEA HOLDING, announces its first order, marking the launch of its commercial operations in the Middle East. The order, placed by Alphamed in the United Arab Emirates, initiates the distribution of 57 licensed medications. This development follows the completion of the transfer of ownership of these products, enabling the company to compete in both public and private markets.
The company plans rapid expansion, targeting neighboring markets such as Bahrain and Qatar. Klea Pharmaceuticals anticipates revenues exceeding €2 million in 2026 and aims for €50 million by 2032.
To strengthen its strategy, Klea has appointed Imad Khalfi as Chief Commercial Officer and Abbas Deesawala as Chief Strategy Officer. These appointments aim to support strong and profitable growth in the MENA region.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all KLEA HOLDING news